Omda MedSciNet

Omda’s oncology medication management solution, Omda Cytodose, uses clinically validated protocols and patient parameters to secure optimal and safer treatment for oncology patients. The system strengthens all aspects of medical care for cancer patients, with a holistic and coherent treatment flow between doctors, pharmacists, and nurses. Omda Cytodose provides support for all adult and pediatric cancers and is suitable for every type of medical cancer treatment, including chemotherapy, immunotherapy, hormone therapy, as well as supportive medication. Originally developed by clinicians at Norway’s leading cancer center, and launched in 2001, Omda Cytodose is widely used by healthcare regions across the Nordics, with millions of orders completed. It has a 15-year record of stability, reliability, and safety. Omda Cytodose is configured with clinically validated chemotherapy protocols based on national and international guidelines.

Effective monitoring of the efficacy of drug treatments and treatment protocols relies on the collection and seamless sharing of comprehensive, timely, and high-quality data. The Omda Compos set of solutions is designed to facilitate robust management and seamless sharing of medical data throughout the clinical ecosystem. This platform ensures data accessibility for users and applications involved in clinical studies and registries, enabling streamlined collaboration and data utilization. Omda Compos QR is the cornerstone of the Compos platform, encompassing a robust database architecture, data warehousing capabilities, user management, and other essential features that ensure data accuracy when managing medical data, from its collection to analysis. Efficiently granting user access and simplifying logging controls and data management are paramount for any registry or trial. In Omda Compos QR, users are assigned roles that determine their access to specific sites.